Li Zhonglin, Lin Hao, Zhou Junwen, Chen Liangzhu, Pan Zhikun, Fang Binghu
Department of Veterinary Medicine, South China Agricultural University, Guangzhou, China.
Chemical R&D Department, Guangdong Dahuanong Animal Health Products Co. Ltd., Yunfu, China.
Drug Dev Res. 2021 Apr;82(2):198-206. doi: 10.1002/ddr.21739. Epub 2020 Sep 21.
Due to the increasing problem of bacterial resistance worldwide, the demand for new antibiotics is becoming increasingly urgent. We wished to: (a) prepare hybrid molecules by linking different pharmacophores by chemical bonds; (b) investigate the antib acterial activity of these hybrids using drug-sensitive and drug-resistant pathogens in vitro and vivo. A series of hybrid molecules with a diester structure were designed and synthesized that linked amoxicillin and derivatives of benzoic acid via a methylene bridge. Synthesized compounds were evaluated for activities against Gram-positive bacteria (Staphylococcus aureus American Type Culture Collection [ATCC] 29213, ATCC 11632; methicillin-resistant S. aureus [MRSA] 11; Escherichia coli ATCC 25922) and Gram-negative bacteria (Salmonella LS677, GD836, GD828, GD3625) by microdilution of broth. Synthesized compounds showed good activity against Gram-positive and Gram-negative bacteria in vitro. In particular, amoxicillin-p-nitrobenzoic acid (6d) showed good activity against Salmonella species and had better activity against methicillin-resistant S. aureus (minimum inhibitory concentration [MIC] = 64 μg/ml) than the reference drug, amoxicillin (MIC = 128 μg/ml). Amoxicillin-p-methoxybenzoic acid (6b) had the best antibacterial activity in vivo (ED = 13.2496 μg/ml). The hybrid molecules of amoxicillin and derivatives of benzoic acid synthesized based on a diester structure can improve the activity of amoxicillin against Salmonella species and even improve the activity against MRSA.
由于全球范围内细菌耐药性问题日益严重,对新型抗生素的需求变得越来越迫切。我们希望:(a) 通过化学键连接不同药效基团来制备杂合分子;(b) 使用体外和体内的药敏和耐药病原体研究这些杂合物的抗菌活性。设计并合成了一系列具有二酯结构的杂合分子,它们通过亚甲基桥连接阿莫西林和苯甲酸衍生物。通过肉汤微量稀释法评估合成化合物对革兰氏阳性菌(金黄色葡萄球菌美国典型培养物保藏中心 [ATCC] 29213、ATCC 11632;耐甲氧西林金黄色葡萄球菌 [MRSA] 11;大肠杆菌 ATCC 25922)和革兰氏阴性菌(沙门氏菌 LS677、GD836、GD828、GD3625)的活性。合成化合物在体外对革兰氏阳性菌和革兰氏阴性菌均表现出良好活性。特别是,阿莫西林 - 对硝基苯甲酸(6d)对沙门氏菌属表现出良好活性,并且对耐甲氧西林金黄色葡萄球菌的活性(最低抑菌浓度 [MIC] = 64 μg/ml)优于参比药物阿莫西林(MIC = 128 μg/ml)。阿莫西林 - 对甲氧基苯甲酸(6b)在体内具有最佳抗菌活性(ED = 13.2496 μg/ml)。基于二酯结构合成的阿莫西林与苯甲酸衍生物的杂合分子可提高阿莫西林对沙门氏菌属的活性,甚至提高对耐甲氧西林金黄色葡萄球菌的活性。